8 Results for "

BRAG2

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "BRAG2" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-P2259
CAS No.: 1404188-93-7
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction [2] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111550
CAS No.: 342795-08-8
Purity:  99.85%
Target:  

Ras MDM-2/p53

Research Areas:  

Cancer

Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC50 of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells .
loading...
    loading...
Cat. No.: HY-111549
CAS No.: 369631-68-5
Purity:  99.91%
Target:  

Arf Family GTPase

Research Areas:  

Cancer

Bragsin1 is a potent, selective and noncompetitive inhibitor of the ArfGEF BRAG2, inhibits Arf GTPase activation, with an IC50 of 3 μM. Bragsin1 binds to PH domain of BRAG2, and is a noncompetitive interfacial inhibitor. Bragsin1 has no effect on the Sec7 domain of human ArfGEFs. Anti-cancer activity .
loading...
    loading...
Cat. No.: HY-111550R
CAS No.: 342795-08-8
Research Areas:  

Cancer

Bragsin2 (Standard) is the analytical standard of Bragsin2 (HY-111550). This product is intended for research and analytical applications. Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC50 of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells .
loading...
    loading...
Cat. No.: HY-111549R
CAS No.: 369631-68-5
Research Areas:  

Cancer

Bragsin1 (Standard) is the analytical standard of Bragsin1 (HY-111549). This product is intended for research and analytical applications. Bragsin1 is a potent, selective and noncompetitive inhibitor of the ArfGEF BRAG2, inhibits Arf GTPase activation, with an IC50 of 3 μM. Bragsin1 binds to PH domain of BRAG2, and is a noncompetitive interfacial inhibitor. Bragsin1 has no effect on the Sec7 domain of human ArfGEFs. Anti-cancer activity .
loading...
    loading...
Cat. No.: HY-P11848
P3LC7LC-P is a blood-brain barrier-permeable BRAG2 ligand with a KD of 6.14 μM. P3LC7LC-P binds to BRAG2, thereby disrupting its interaction with the GluA2 subunit of the AMPA receptor and inhibiting glutamate-induced GluA2 endocytosis. P3LC7LC-P exerts neuroprotective effects in oxygen-glucose deprivation-induced and glutamate-induced neurotoxicity models, reduces ROS accumulation and inhibits apoptosis, and reduces cerebral infarct size in a rat model of transient middle cerebral artery occlusion. P3LC7LC-P can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-P11892
c10c-G1V3 is a BRAG2 binder with a Kd value of 7.37 μM. c10c-G1V3 binds to BRAG2, thereby disrupting its interaction with GluA2 and blocking GluA2 endocytosis and AMPAR subunit switching. c10c-G1V3 reduces glutamate-induced intracellular reactive oxygen species (ROS) accumulation and cell apoptosis (apoptosis). c10c-G1V3 decreases infarct volume in the transient middle cerebral artery occlusion model. c10c-G1V3 can be used in studies related to ischemic stroke .
loading...
    loading...
Cat. No.: HY-RS06888
Research Areas:  

Others

IQSEC1 Human Pre-designed siRNA Set A contains three designed siRNAs for IQSEC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...